Hellenic Capital Market Commission

China Jo-Jo Drugstores Granted A Second Extension to Meet Nasdaq Minimum Bid Price Requirement

Retrieved on:

Thursday, December 14, 2023

Capital market, Hellenic Capital Market Commission, Failure, Calendar, Auction

HANGZHOU, China, Dec. 14, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) (the "Company"), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that on December 13, 2023, the Company received another 180 calendar day extension from Nasdaq's Listing Qualifications Department ("Nasdaq") to meet Nasdaq's continuing listing requirements by maintaining a minimum bid price per share of $1.00 for a minimum of 10 consecutive trading days (the "Minimum Bid Price Rules").

Key Points:

HANGZHOU, China, Dec. 14, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) (the "Company"), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that on December 13, 2023, the Company received another 180 calendar day extension from Nasdaq's Listing Qualifications Department ("Nasdaq") to meet Nasdaq's continuing listing requirements by maintaining a minimum bid price per share of $1.00 for a minimum of 10 consecutive trading days (the "Minimum Bid Price Rules").
The Company now has until June 10, 2024 to regain compliance with the Minimum Bid Price Rules.
Such determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement, and the Company's written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.
As previously reported, the Company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules 5550(a)(2) on June 15, 2023, and was given until December 12, 2023 to regain compliance pursuant to Nasdaq Listing Rules 5810(c)(3)(A).

PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market

Retrieved on:

Monday, June 5, 2023

Capital market, Hellenic Capital Market Commission, Calendar, US, Letter, Cryptocurrency

The Company was given a period of 180 calendar days, or until June 5, 2023, to regain compliance with the minimum bid price requirement.

Key Points:

The Company was given a period of 180 calendar days, or until June 5, 2023, to regain compliance with the minimum bid price requirement.
In order to be provided with a second 180-day compliance period, the Company submitted an application to transfer the listing of its Ordinary Shares from the Nasdaq Global Market to the Nasdaq Capital Market.
The Company’s Ordinary Shares continue to trade under the symbol “PYPD” and trading of its Ordinary Shares will not be affected by this transfer.
The Nasdaq Capital Market is a continuous trading market that operates in substantially the same manner as The Nasdaq Global Market.

Crypto.com Obtains Major Payment Institution Licence from Monetary Authority of Singapore

Retrieved on:

Thursday, June 1, 2023

SINGAPORE, June 1, 2023 /PRNewswire/ -- Crypto.com announced today that it has received its Major Payment Institution (MPI) licence for Digital Payment Token (DPT) services from the Monetary Authority of Singapore (MAS). This announcement follows Crypto.com receiving its in-principle approval from MAS in June 2022. With this licence, Crypto.com can continue to extend its Digital Payment Token (DPT) services to customers in Singapore.

Key Points:

SINGAPORE, June 1, 2023 /PRNewswire/ -- Crypto.com announced today that it has received its Major Payment Institution (MPI) licence for Digital Payment Token (DPT) services from the Monetary Authority of Singapore (MAS).
With this licence, Crypto.com can continue to extend its Digital Payment Token (DPT) services to customers in Singapore.
"The Monetary Authority of Singapore is recognized globally as a regulator that ensures responsible innovation of the digital assets sector," said Kris Marszalek, CEO of Crypto.com.
"The Major Payment Institution licence underscores our ongoing commitment to build with the Web3 community in Singapore."

Crypto.com Obtains Major Payment Institution Licence from Monetary Authority of Singapore

Retrieved on:

Thursday, June 1, 2023

SINGAPORE, June 1, 2023 /PRNewswire/ -- Crypto.com announced today that it has received its Major Payment Institution (MPI) licence for Digital Payment Token (DPT) services from the Monetary Authority of Singapore (MAS). This announcement follows Crypto.com receiving its in-principle approval from MAS in June 2022. With this licence, Crypto.com can continue to extend its Digital Payment Token (DPT) services to customers in Singapore.

Key Points:

SINGAPORE, June 1, 2023 /PRNewswire/ -- Crypto.com announced today that it has received its Major Payment Institution (MPI) licence for Digital Payment Token (DPT) services from the Monetary Authority of Singapore (MAS).
With this licence, Crypto.com can continue to extend its Digital Payment Token (DPT) services to customers in Singapore.
"The Monetary Authority of Singapore is recognized globally as a regulator that ensures responsible innovation of the digital assets sector," said Kris Marszalek, CEO of Crypto.com.
"The Major Payment Institution licence underscores our ongoing commitment to build with the Web3 community in Singapore."

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

Retrieved on:

Friday, May 5, 2023

Capital market, Hellenic Capital Market Commission, ADS, American depositary receipt, Cryptocurrency

LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that it has received approval from Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) from the Nasdaq Global Market to the Nasdaq Capital Market.

Key Points:

LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that it has received approval from Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) from the Nasdaq Global Market to the Nasdaq Capital Market.
The Nasdaq Global Market and the Nasdaq Capital Market are each market tiers of Nasdaq and the Nasdaq Capital Market is a continuous trading market that operates in the same manner as the Nasdaq Global Market.
The approval by Nasdaq was based upon the Company meeting the applicable market value of publicly held shares requirement for continued listing and all other applicable requirements for initial listing on the Capital Market, except for the bid price requirement.
In connection with the transfer to the Nasdaq Capital Market, the Company became eligible for an additional 180-day period (or until October 30, 2023) to regain compliance with the requirement set forth in Nasdaq Listing Rule 5450(a)(1) that the bid price of the Company’s ADSs meet or exceed $1.00 per ADS for at least ten consecutive business days.

Akso Health Group Granted Additional 180 Calendar Day Grace Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Retrieved on:

Thursday, April 27, 2023

Capital market, Hellenic Capital Market Commission, ADS, AHG, Calendar, Letter, Auction

BEIJING, April 27, 2023 (GLOBE NEWSWIRE) -- Akso Health Group (NASDAQ: AHG) (“Akso Health” the “Company” or “we”), today announced that the Company has received a notification letter from the Nasdaq Stock Market LLC (“Nasdaq”) on April 25, 2023, notifying the Company that it has been granted an additional 180-day compliance period, or until October 23, 2023 to regain compliance with Nasdaq’s minimum bid price rule.

Key Points:

BEIJING, April 27, 2023 (GLOBE NEWSWIRE) -- Akso Health Group (NASDAQ: AHG) (“Akso Health” the “Company” or “we”), today announced that the Company has received a notification letter from the Nasdaq Stock Market LLC (“Nasdaq”) on April 25, 2023, notifying the Company that it has been granted an additional 180-day compliance period, or until October 23, 2023 to regain compliance with Nasdaq’s minimum bid price rule.
Previously, in a notification letter dated October 26, 2022, Nasdaq had notified the Company that, based on the previous 30 consecutive business days, the Company’s ADSs no longer met the minimum $1 bid price per share requirement.
Therefore, in accordance with Nasdaq’s Listing Rules, the Company was provided 180 calendar days, or until April 24, 2023, to regain compliance.
The Company will actively monitor the closing bid price of its ADSs between now and October 23, 2023 and intends to consider all available options to resolve the deficiency and regain compliance within the additional compliance period provided.

ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital Market

Retrieved on:

Monday, April 17, 2023

Capital market, Hellenic Capital Market Commission, ADS, American depositary receipt, Cryptocurrency

Cambridge, MA (U.S.) and Lyon (France), April 17, 2023 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it received approval from The Nasdaq Stock Market LLC ("Nasdaq") dated April 12, 2023, to transfer the listing of its American Depositary Shares representing ordinary shares of the Company (“ADSs”) from The Nasdaq Global Select Market to The Nasdaq Capital Market.

Key Points:

Cambridge, MA (U.S.) and Lyon (France), April 17, 2023 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it received approval from The Nasdaq Stock Market LLC ("Nasdaq") dated April 12, 2023, to transfer the listing of its American Depositary Shares representing ordinary shares of the Company (“ADSs”) from The Nasdaq Global Select Market to The Nasdaq Capital Market.
The Company’s ADSs continue to trade under the symbol “ERYP” and trading of its ADSs will be unaffected by this transfer.
The Nasdaq Capital Market is a continuous trading market that operates in substantially the same manner as The Nasdaq Global Select Market.
In connection with the transfer to the Nasdaq Capital Market, Nasdaq granted the Company an additional 180-day period (or until October 2, 2023) to regain compliance with the requirement set forth in Nasdaq Listing Rule 5450(a)(1) that the bid price of the Company’s ADSs meet or exceed $1.00 per ADS for at least ten consecutive business days.

LIZHI Receives Additional Compliance Period to Regain Minimum Bid Price

Retrieved on:

Wednesday, April 12, 2023

Capital market, Hellenic Capital Market Commission, ADS, Calendar, US, Letter, Cryptocurrency, Auction

The Company was given a compliance period of 180 calendar days, or until April 10, 2023, to regain compliance with the minimum bid price requirement.

Key Points:

The Company was given a compliance period of 180 calendar days, or until April 10, 2023, to regain compliance with the minimum bid price requirement.
As a result of the transfer to the Nasdaq Capital Market, Nasdaq granted the Company a second period of 180 calendar days, or until October 9, 2023, to regain compliance with the minimum bid price requirement for continued listing.
To regain compliance, the closing bid price of the Company’s ADSs must meet or exceed US$1.00 per ADS for a minimum of 10 consecutive business days on or prior to October 9, 2023.
The Company intends to continue to actively monitor the minimum bid price requirement and, as appropriate, will consider available options to resolve any deficiencies and regain compliance.

Cemtrex Regains Compliance with Nasdaq Listing Requirements

Retrieved on:

Thursday, February 9, 2023

CUSIP, Capital market, Hellenic Capital Market Commission, Auction

Brooklyn, NY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, announced today that it has received notice from the Nasdaq Stock Market LLC (Nasdaq) on February 8, 2023 informing the Company that it’s common stock has regained full compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.

Key Points:

Brooklyn, NY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, announced today that it has received notice from the Nasdaq Stock Market LLC (Nasdaq) on February 8, 2023 informing the Company that it’s common stock has regained full compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.
Cemtrex previously received a notification letter from the Listing Qualifications Department of Nasdaq on January 26, 2023 notifying the Company that it has not regained compliance with Listing Rule 5550(a)(2) and accordingly would be delisted from the Capital Market.
Cemtrex, however, was granted an additional 180 days, or until July 24, 2023, to regain compliance with the Minimum Bid Price Requirement, a requirement which Cemtrex met on February 7, 2023.
In connection with the reverse split, the Company’s common stock continues trading on Nasdaq under the symbol “CETX” but now trades under a new CUSIP Number, 15130G 709.

WiSA Technologies Granted Additional 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirements

Retrieved on:

Tuesday, December 27, 2022

Audio, Video, Consumer Electronics, Mobile, Wireless, Other Technology, Technology, Calendar, Common stock, Common, Hellenic Capital Market Commission, Letter, WISA, Capital market, Auction

WiSA Technologies, Inc. (Nasdaq: WISA), a developer of spatial, wireless sound technology for smart devices and next-generation home entertainment systems, today announced it received a notification letter from Nasdaq Stock Market LLC that the Company has been granted an additional 180-day compliance period, or until June 20, 2023, to regain compliance with Nasdaq's minimum bid price rule.

Key Points:

WiSA Technologies, Inc. (Nasdaq: WISA), a developer of spatial, wireless sound technology for smart devices and next-generation home entertainment systems, today announced it received a notification letter from Nasdaq Stock Market LLC that the Company has been granted an additional 180-day compliance period, or until June 20, 2023, to regain compliance with Nasdaq's minimum bid price rule.
There is no immediate effect on the listing or trading of the Company's Common Stock, which will continue to trade on the Nasdaq Capital Market under the symbol "WISA".
Therefore, in accordance with Nasdaq's Listing Rules, the Company was provided 180 calendar days, or until December 20, 2022, to regain compliance, and an additional 180 days to regain compliance was granted by Nasdaq on December 21, 2022.
The Company intends to monitor the closing bid price of its Common Stock and represented to Nasdaq that it will cure the deficiency by effecting a reverse stock split, if necessary, in order to regain compliance with the minimum bid price requirement within the second compliance period.